Background There is accumulating evidence for an overly activated immune response in
severe COVID-19, with several studies exploring the therapeutic role of immunomodulation …

Background Currently, the data regarding the effectiveness and safety of tocilizumab as
treatment for COVID-19 infection is still conflicting. This study aims to give clear evidence …

Recent studies reported the presence of pre-existing autoantibodies (auto-Abs) neutralizing
type I interferons (IFNs) in at least 15% of patients with critical COVID-19 pneumonia. In one …

Tocilizumab has been repurposed against the 'cytokine storm'in the setting of coronavirus
disease 2019 (COVID‐19). Our aim was to evaluate the efficacy of tocilizumab in the …

Objectives To assess the characteristics and risk factors for mortality in patients with severe
coronavirus disease-2019 (COVID-19) treated with tocilizumab (TCZ), alone or in …

Objectives Currently published papers and clinical guidelines regarding the effects of
tocilizumab in severe and critical COVID-19 are contradictory. The aim of this meta-analysis …

Introduction The results of studies of tocilizumab (TCZ) in COVID‐19 are contradictory. Our
study aims to update medical evidence from controlled observational studies and …

Background: COVID-19 has several overlapping phases. Treatments to date have focused
on the late stage of disease in hospital. Yet, the pandemic is by propagated by the viral …

Introduction We systematically assessed benefits and harms of tocilizumab (TCZ), which is
an antibody blocking IL-6 receptors, in hospitalized COVID-19 patients. Methods Five …

Over 50 million people have been infected with the SARS-CoV-2 virus, while around 1
million have died due to COVID-19 disease progression. COVID-19 presents flu-like …